WA UNIV SCH MED
GenericsWA UNIV SCH MED is a generic drug manufacturer focused on Oncology.
WA UNIV SCH MED's Key Drugs
WA UNIV SCH MED's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
WA UNIV SCH MED's Recent FDA Approvals
New NDA/BLA approvals for WA UNIV SCH MED over the last two years — novel drugs only, excluding generics and label supplements.
WA UNIV SCH MED's Therapeutic Areas
WA UNIV SCH MED's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
WA UNIV SCH MED's Top Competitors
WA UNIV SCH MED's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
WA UNIV SCH MED Pipeline Snapshot
Active clinical trials for WA UNIV SCH MED across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-02-07
- Latest
- 2026-02-13
- Applications
- 2